Sep 3, 2024, 12:00 AM
Sep 3, 2024, 12:00 AM

Nikon opens BioImaging Labs in Germany, Switzerland, and UK

Highlights
  • Nikon has opened three new Nikon BioImaging Lab sites in Europe, located in Germany, Switzerland, and the UK.
  • These labs provide advanced microscope-based imaging and analysis services to support biotech and pharmaceutical research.
  • The expansion enhances Nikon's collaboration with the scientific community and strengthens research capabilities across Europe.
Story

Nikon Europe B.V. has announced the opening of three new Nikon BioImaging Lab (NBIL) sites in Europe, located at BioLabs Heidelberg in Germany, iCITY Basel in Switzerland, and Babraham Research Campus in Cambridge, UK. These labs are part of Nikon's strategy to enhance support for the biotech and pharmaceutical sectors by providing advanced microscope-based imaging and analysis services. The new facilities are designed to cater to the needs of life science researchers and biotech companies, offering flexible spaces for collaboration. The NBILs will provide a range of contract research services, including assay development, cell culture, sample preparation, data acquisition, and data analysis. This expansion builds on the existing capabilities of the main hub at Leiden BioScience Park in the Netherlands, allowing Nikon to offer comprehensive support to scientists and researchers across Europe. The labs are equipped with cutting-edge microscopy instrumentation and staffed by expert biologists and microscopists. The lab at BioLabs Heidelberg is already operational and will host an introductory workshop on September 11, featuring guest speakers and hands-on sessions with the ECLIPSE Ji Digital Microscope. Meanwhile, the Babraham Research Campus lab is set to open on September 23, with an event that includes talks from leading researchers and panel discussions. This expansion is part of Nikon's ongoing commitment to collaborate with the scientific community, aiming to meet current research needs while also fostering the development of innovative solutions for future challenges in drug discovery and healthcare.

Opinions

You've reached the end